titanium dioxide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4237 13463-67-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • titanium dioxide
  • titanium oxide
used medically as protectant against externally caused irritation & sunlight; high concentrations of dust may cause irritation to respiratory tract; RN given refers to titanium oxide (TiO2); structure
  • Molecular weight: 79.87
  • Formula: O2Ti
  • CLOGP: -1.32
  • LIPINSKI: None
  • HAC: 2
  • HDO: 0
  • TPSA: 34.14
  • ALOGS:
  • ROTB: 0

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT3,ALK,AURKA,AURKC,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,IRAK1,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MELK,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIM1,PIM2,PIM3,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 75
kinase-selectivity-class CDK9,DYRK1B,GRK2,GSK3B,HIPK2,MAP2K6,MAP3K14,MAPK7,PIK3CG,PRKDC 10
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Oct. 5, 2006 FDA LOREAL USA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 878.74 18.56 326 19656 37644 90570821
Chronic sinusitis 335.34 18.56 143 19839 23659 90584806
Paraesthesia oral 296.27 18.56 143 19839 31516 90576949
Vaginal flatulence 293.73 18.56 109 19873 12529 90595936
Female genital tract fistula 284.02 18.56 117 19865 17751 90590714
Procedural pain 280.27 18.56 140 19842 33220 90575245
Proctitis 273.76 18.56 109 19873 15150 90593315
Radiculopathy 270.01 18.56 114 19868 18391 90590074
Vaginal discharge 251.40 18.56 110 19872 19354 90589111
Oral candidiasis 186.29 18.56 109 19873 35346 90573119
Colitis ulcerative 155.45 18.56 119 19863 60147 90548318
Frequent bowel movements 148.11 18.56 113 19869 56822 90551643
Dyspepsia 139.46 18.56 194 19788 197966 90410499
Joint dislocation 137.38 18.56 98 19884 44484 90563981
Seronegative arthritis 137.00 18.56 71 19911 18163 90590302
Haematochezia 136.40 18.56 118 19864 70795 90537670
Therapeutic product effect incomplete 129.28 18.56 185 19797 193711 90414754
Joint stiffness 126.66 18.56 118 19864 77924 90530541
Rectal haemorrhage 124.55 18.56 120 19862 82624 90525841
Colitis 123.74 18.56 111 19871 69831 90538634
Weight decreased 121.34 18.56 262 19720 379648 90228817
Prescribed underdose 107.65 18.56 106 19876 74913 90533552
Osteoporosis 102.21 18.56 116 19866 96415 90512050
Sciatica 87.83 18.56 110 19872 101272 90507193
Walking aid user 82.62 18.56 66 19916 35440 90573025
Infusion related reaction 80.92 18.56 238 19744 416542 90191923
Retinitis 80.06 18.56 67 19915 38391 90570074
Lupus vulgaris 78.66 18.56 71 19911 44988 90563477
Wound infection 77.50 18.56 106 19876 106296 90502169
Psoriasis 75.88 18.56 125 19857 147629 90460836
Lupus-like syndrome 71.88 18.56 70 19912 48776 90559689
Joint range of motion decreased 71.33 18.56 116 19866 135527 90472938
Upper respiratory tract infection 70.57 18.56 112 19870 128206 90480259
Laryngitis 69.62 18.56 70 19912 50683 90557782
Visual impairment 63.98 18.56 109 19873 132256 90476209
Broncholithiasis 60.72 18.56 14 19968 293 90608172
Foot deformity 60.27 18.56 70 19912 59581 90548884
Road traffic accident 57.88 18.56 93 19889 107533 90500932
Lymph node calcification 57.39 18.56 14 19968 376 90608089
Anti-cyclic citrullinated peptide antibody 55.77 18.56 47 19935 27174 90581291
Hypercholesterolaemia 54 18.56 87 19895 100805 90507660
Osteoarthritis 52.33 18.56 126 19856 195604 90412861
Type 2 diabetes mellitus 51.33 18.56 128 19854 203116 90405349
Fatigue 51.05 18.56 112 19870 1153911 89454554
Carbuncle 51.04 18.56 17 19965 1419 90607046
Knee arthroplasty 44.88 18.56 72 19910 83110 90525355
Monoclonal immunoglobulin present 44.54 18.56 17 19965 2107 90606358
Hypothalamo-pituitary disorder 43.57 18.56 17 19965 2235 90606230
Adjustment disorder with depressed mood 43.52 18.56 58 19924 56695 90551770
Dislocation of vertebra 42.61 18.56 57 19925 55911 90552554
Spinal fusion surgery 42.49 18.56 29 19953 12254 90596211
Liver function test increased 42.47 18.56 71 19911 84784 90523681
Hepatic cirrhosis 41.55 18.56 60 19922 63193 90545272
Spondylitis 40.99 18.56 30 19952 14148 90594317
Hip arthroplasty 39.80 18.56 65 19917 76143 90532322
Disability 39.79 18.56 47 19935 40698 90567767
Pyrexia 38.44 18.56 263 19719 660222 89948243
Exostosis 37.26 18.56 52 19930 53082 90555383
Red blood cell sedimentation rate increased 37.25 18.56 66 19916 82529 90525936
Amyloid arthropathy 37.23 18.56 14 19968 1666 90606799
Erythema 37.06 18.56 123 19859 229123 90379342
Wheezing 36.08 18.56 125 19857 237955 90370510
Bone erosion 35.86 18.56 51 19931 52970 90555495
Lower limb fracture 34.63 18.56 65 19917 84948 90523517
Prescribed overdose 34.13 18.56 70 19912 97555 90510910
Bronchial wall thickening 34.00 18.56 14 19968 2117 90606348
Asthma-chronic obstructive pulmonary disease overlap syndrome 33.73 18.56 18 19964 4881 90603584
Total lung capacity increased 33.31 18.56 18 19964 5003 90603462
Deep vein thrombosis postoperative 32.47 18.56 57 19925 70752 90537713
Cough 32.00 18.56 21 19961 368941 90239524
Lichen nitidus 31.96 18.56 7 19975 115 90608350
Drug hypersensitivity 30.91 18.56 34 19948 463575 90144890
Pulmonary fibrosis 30.65 18.56 71 19911 107432 90501033
Asthenia 30.53 18.56 44 19938 533707 90074758
Grip strength decreased 29.60 18.56 64 19918 92512 90515953
Contraindicated product administered 29.46 18.56 17 19965 320122 90288343
Swollen joint count increased 29.06 18.56 71 19911 111135 90497330
Wrist deformity 28.38 18.56 14 19968 3224 90605241
Overweight 27.91 18.56 17 19965 5917 90602548
Fibrosis 27.86 18.56 17 19965 5935 90602530
Product use issue 26.99 18.56 20 19962 329899 90278566
Nasal polyps 26.97 18.56 21 19961 10859 90597606
Oedema 26.80 18.56 101 19881 200194 90408271
Autoimmune disorder 26.79 18.56 55 19927 76689 90531776
Constipation 26.36 18.56 127 19855 280268 90328197
Abdominal pain upper 26.15 18.56 21 19961 332653 90275812
Dyspnoea 26.11 18.56 103 19879 880852 89727613
Maternal exposure during pregnancy 25.58 18.56 25 19957 360038 90248427
Ear infection 25.54 18.56 51 19931 69724 90538741
Hypotension 25.01 18.56 21 19961 325376 90283089
Drug interaction 24.98 18.56 15 19967 276438 90332027
Irritable bowel syndrome 24.83 18.56 101 19881 207347 90401118
Diarrhoea 24.65 18.56 115 19867 939075 89669390
Psoriatic arthropathy 24.10 18.56 107 19875 228228 90380237
Urticaria 24.09 18.56 134 19848 312600 90295865
Bronchiectasis 23.89 18.56 27 19955 22303 90586162
Hypomania 23.87 18.56 18 19964 8879 90599586
Oedema peripheral 23.65 18.56 116 19866 257799 90350666
Fall 23.55 18.56 44 19938 481766 90126699
Nephropathy 23.27 18.56 18 19964 9217 90599248
Acute kidney injury 23.04 18.56 22 19960 320365 90288100
Therapeutic product effect decreased 22.47 18.56 17 19965 277554 90330911
Jaundice cholestatic 21.94 18.56 18 19964 10025 90598440
Disease progression 21.93 18.56 4 19978 156611 90451854
Drug-induced liver injury 21.85 18.56 56 19926 90262 90518203
Treatment failure 21.70 18.56 21 19961 303907 90304558
Exposure during pregnancy 21.44 18.56 13 19969 238397 90370068
Aplastic anaemia 21.38 18.56 20 19962 13249 90595216
Sarcoidosis 20.98 18.56 18 19964 10655 90597810
Delirium 20.55 18.56 60 19922 104299 90504166
Hyperhidrosis 20.16 18.56 3 19979 136302 90472163
Cholelithiasis 19.96 18.56 39 19943 52467 90555998
Pulmonary pain 19.92 18.56 13 19969 5101 90603364
Dyslipidaemia 19.78 18.56 17 19965 10090 90598375
Urinary tract infection 19.71 18.56 23 19959 305609 90302856
Death 19.51 18.56 45 19937 456506 90151959
Neutropenia 19.22 18.56 13 19969 224891 90383574

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anal inflammation 147.10 20.14 34 3159 2195 42615947
SARS-CoV-2 test negative 138.28 20.14 31 3162 1744 42616398
Accident 111.01 20.14 34 3159 6469 42611673
Proctalgia 108.10 20.14 34 3159 7059 42611083
Haemorrhoids 75.66 20.14 33 3160 17064 42601078
Body temperature increased 73.24 20.14 34 3159 20324 42597818
Choroiditis 69.95 20.14 17 3176 1358 42616784
Endophthalmitis 58.28 20.14 19 3174 4414 42613728
Visual acuity reduced 41.36 20.14 22 3171 17528 42600614
Intraocular pressure increased 40.56 20.14 16 3177 6417 42611725
Condition aggravated 35.47 20.14 67 3126 260687 42357455
Completed suicide 34.13 20.14 39 3154 96426 42521716
Eye pain 33.64 20.14 19 3174 17011 42601131
Febrile neutropenia 28.08 20.14 50 3143 185653 42432489
Chills 26.67 20.14 34 3159 94032 42524110
Chondritis 24.12 20.14 5 3188 193 42617949
Back pain 23.80 20.14 40 3153 141736 42476406
Vomiting 21.93 20.14 59 3134 289664 42328478
Pyrexia 20.22 20.14 70 3123 393972 42224170

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 428.95 15.17 147 15153 21512 110552487
Chronic sinusitis 385.43 15.17 141 15159 24943 110549056
Vaginal flatulence 343.68 15.17 108 15192 12036 110561963
Female genital tract fistula 342.25 15.17 116 15184 16403 110557596
Paraesthesia oral 341.68 15.17 140 15160 33531 110540468
Procedural pain 327.57 15.17 138 15162 35427 110538572
Radiculopathy 313.08 15.17 113 15187 19223 110554776
Proctitis 308.48 15.17 108 15192 16819 110557180
Vaginal discharge 306.31 15.17 109 15191 17799 110556200
Oral candidiasis 210.15 15.17 109 15191 44651 110529348
Therapeutic product effect incomplete 186.50 15.17 190 15110 223615 110350384
Colitis ulcerative 176.30 15.17 118 15182 77245 110496754
Frequent bowel movements 172.63 15.17 113 15187 71277 110502722
Rectal haemorrhage 144.49 15.17 125 15175 119708 110454291
Dyspepsia 142.66 15.17 153 15147 190812 110383187
Haematochezia 136.24 15.17 119 15181 115405 110458594
Colitis 132.05 15.17 111 15189 102212 110471787
Anal inflammation 117.85 15.17 33 15267 2463 110571536
Proctalgia 110.73 15.17 48 15252 13174 110560825
SARS-CoV-2 test negative 108.70 15.17 30 15270 2123 110571876
Infusion related reaction 83.36 15.17 171 15129 380991 110193008
Weight decreased 76.56 15.17 187 15113 467870 110106129
Erythema 73.67 15.17 139 15161 291308 110282691
Accident 70.22 15.17 33 15267 10919 110563080
Broncholithiasis 62.11 15.17 13 15287 279 110573720
Pyrexia 59.07 15.17 263 15037 898002 109675997
Carbuncle 58.49 15.17 17 15283 1450 110572549
Lymph node calcification 55.97 15.17 13 15287 456 110573543
Malaise 55.39 15.17 211 15089 671608 109902391
Choroiditis 52.57 15.17 16 15284 1599 110572400
Psoriasis 51.55 15.17 79 15221 139914 110434085
Constipation 51.20 15.17 136 15164 357650 110216349
Monoclonal immunoglobulin present 49.30 15.17 17 15283 2523 110571476
Hypothalamo-pituitary disorder 47.41 15.17 17 15283 2829 110571170
Total lung capacity increased 44.24 15.17 19 15281 5093 110568906
Amyloid arthropathy 43.61 15.17 14 15286 1666 110572333
Asthma-chronic obstructive pulmonary disease overlap syndrome 40.31 15.17 19 15281 6325 110567674
Abdominal pain 37.28 15.17 155 15145 512834 110061165
Sciatica 36.64 15.17 54 15246 92345 110481654
Wrist deformity 34.85 15.17 14 15286 3175 110570824
Nasal polyps 34.59 15.17 22 15278 13178 110560821
Overweight 33.97 15.17 17 15283 6447 110567552
Lichen nitidus 33.68 15.17 7 15293 145 110573854
Endophthalmitis 32.93 15.17 18 15282 8169 110565830
Haemorrhoids 32.78 15.17 32 15268 35640 110538359
Hypomania 31.80 15.17 19 15281 10191 110563808
Bronchial wall thickening 31.36 15.17 13 15287 3194 110570805
Fibrosis 31.28 15.17 17 15283 7625 110566374
Pain 28.28 15.17 227 15073 954728 109619271
Sarcoidosis 28.17 15.17 19 15281 12560 110561439
Cholelithiasis 27.98 15.17 39 15261 63383 110510616
Body temperature increased 27.73 15.17 36 15264 54677 110519322
Soft tissue necrosis 27.12 15.17 9 15291 1189 110572810
Anaemia 27.11 15.17 148 15152 546938 110027061
Osteoporosis 26.36 15.17 45 15255 87107 110486892
Rhinitis allergic 26.36 15.17 21 15279 17901 110556098
Body height decreased 26.18 15.17 17 15283 10546 110563453
Fatigue 26.12 15.17 84 15216 1215874 109358125
Jaundice cholestatic 25.61 15.17 19 15281 14589 110559410
Completed suicide 24.04 15.17 81 15219 242300 110331699
Movement disorder 23.39 15.17 27 15273 36377 110537622
Bronchiectasis 23.34 15.17 27 15273 36466 110537533
Death 23.31 15.17 38 15262 698831 109875168
Pulmonary pain 23.02 15.17 13 15287 6280 110567719
Nephropathy 22.46 15.17 17 15283 13450 110560549
Headache 22.02 15.17 202 15098 882175 109691824
Bone density decreased 21.90 15.17 18 15282 16024 110557975
Intraocular pressure increased 21.00 15.17 15 15285 10861 110563138
Dyslipidaemia 19.91 15.17 17 15283 15948 110558051
Aplastic anaemia 19.03 15.17 20 15280 24288 110549711
Schizophrenia 18.98 15.17 19 15281 21807 110552192
Therapeutic product effect delayed 18.43 15.17 10 15290 4469 110569530
Renal cyst 18.01 15.17 17 15283 18155 110555844
Drug interaction 17.81 15.17 26 15274 500157 110073842
Cardiac murmur 17.07 15.17 19 15281 24609 110549390
Eye pain 16.66 15.17 27 15273 50072 110523927
Visual acuity reduced 16.04 15.17 21 15279 32152 110541847
Joint swelling 15.78 15.17 23 15277 442822 110131177
Joint stiffness 15.63 15.17 31 15269 67212 110506787

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
MeSH PA D001672 Biocompatible Materials
MeSH PA D003879 Dermatologic Agents
MeSH PA D004396 Coloring Agents
MeSH PA D011837 Radiation-Protective Agents
MeSH PA D011838 Radiation-Sensitizing Agents
MeSH PA D013473 Sunscreening Agents
MeSH PA D017319 Photosensitizing Agents
MeSH PA D020011 Protective Agents
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:77182 food colouring

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
15FIX9V2JP UNII
4019139 VUID
N0000179267 NUI
D01931 KEGG_DRUG
4019139 VANDF
C0076733 UMLSCUI
CHEBI:32234 CHEBI
CHEMBL1201136 ChEMBL_ID
26042 PUBCHEM_CID
DB09536 DRUGBANK_ID
C009495 MESH_SUPPLEMENTAL_RECORD_UI
38323 RXNORM
NOCODE MMSL
001911 NDDF
432929006 SNOMEDCT_US
62036000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
TOTAL DEFENSE REPAIR BROAD SPECTRUM SPF 34 Sunscreen (Tinted) HUMAN OTC DRUG LABEL 4 0023-5497 LOTION 35 mg TOPICAL OTC Monograph Drug 13 sections
Essential Defense Mineral Shield Broad Spectrum SPF 32 TINTED Sunscreen HUMAN OTC DRUG LABEL 2 0023-5675 LOTION 50 mg TOPICAL OTC Monograph Drug 13 sections
Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen HUMAN OTC DRUG LABEL 2 0023-5703 LOTION 50 mg TOPICAL OTC Monograph Drug 13 sections
Solbar Shield SPF40 HUMAN OTC DRUG LABEL 2 0096-0682 CREAM 0.05 g TOPICAL OTC Monograph Drug 8 sections
Solbar Shield SPF40 HUMAN OTC DRUG LABEL 2 0096-0682 CREAM 0.05 g TOPICAL OTC Monograph Drug 8 sections
SOLBAR SUNSCREEN 40 SHIELD HUMAN OTC DRUG LABEL 2 0096-0692 CREAM 50 mg TOPICAL OTC Monograph Drug 10 sections
Cetaphil Sheer Mineral Sunscreen Stick SPF 50 HUMAN OTC DRUG LABEL 2 0299-4108 STICK 60 mg TOPICAL OTC Monograph Drug 12 sections
Cetaphil Sheer Mineral Sunscreen SPF 30 HUMAN OTC DRUG LABEL 2 0299-4111 LOTION 30 mg TOPICAL OTC Monograph Drug 12 sections
Cetaphil Sheer Mineral Sunscreen SPF 50 HUMAN OTC DRUG LABEL 2 0299-4122 LOTION 90 mg TOPICAL OTC Monograph Drug 12 sections
Cetaphil Redness Relieving Daily Facial Moisturizer with sunscreen SPF 40 HUMAN OTC DRUG LABEL 2 0299-4138 CREAM 101 mg TOPICAL OTC Monograph Drug 10 sections
Cetaphil Sun Tinted Face SPF 40 HUMAN OTC DRUG LABEL 2 0299-4145 LOTION 101 mg TOPICAL OTC Monograph Drug 10 sections
Cetaphil Daily Facial Moisturizer with suncreen SPF 50 HUMAN OTC DRUG LABEL 5 0299-4930 LOTION 57 mg TOPICAL OTC Monograph Drug 12 sections
Almay Age Smart Shade CC Luminous Primer SPF 15 HUMAN OTC DRUG LABEL 2 0311-0706 LIQUID 4.30 mg TOPICAL OTC Monograph Drug 10 sections
Almay Healthy Biome Makeup HUMAN OTC DRUG LABEL 5 0311-0723 EMULSION 5.80 mg TOPICAL OTC Monograph Drug 9 sections
Almay Healthy Biome MakeupFair HUMAN OTC DRUG LABEL 5 0311-0737 EMULSION 5.80 mg TOPICAL OTC Monograph Drug 9 sections
Almay Healthy Biome MakeupLight HUMAN OTC DRUG LABEL 5 0311-0738 EMULSION 5.80 mg TOPICAL OTC Monograph Drug 9 sections
Almay Healthy Biome MakeupMedium HUMAN OTC DRUG LABEL 5 0311-0739 EMULSION 5.80 mg TOPICAL OTC Monograph Drug 9 sections
Almay Healthy Biome MakeupGolden HUMAN OTC DRUG LABEL 5 0311-0740 EMULSION 5.80 mg TOPICAL OTC Monograph Drug 9 sections
Almay Healthy Biome MakeupTan HUMAN OTC DRUG LABEL 5 0311-0741 EMULSION 5.80 mg TOPICAL OTC Monograph Drug 9 sections
ALMAY SMART SHADE ANTI-AGING SKINTONE MATCHING MAKEUP SPF 20 HUMAN OTC DRUG LABEL 2 0311-0749 LIQUID 5.50 mg TOPICAL OTC Monograph Drug 10 sections
ALMAY SMART SHADE ANTI-AGING SKINTONE MATCHING MAKEUP SPF 20Medium HUMAN OTC DRUG LABEL 2 0311-0750 LIQUID 5.50 mg TOPICAL OTC Monograph Drug 10 sections
Almay Smart Shade Skintone Matching MakeupMedium HUMAN OTC DRUG LABEL 2 0311-0752 LIQUID 4.80 mg TOPICAL OTC Monograph Drug 10 sections
ALMAY SMART SHADE ANTI-AGING SKINTONE MATCHING MAKEUP SPF 20Light HUMAN OTC DRUG LABEL 2 0311-0783 LIQUID 5.50 mg TOPICAL OTC Monograph Drug 10 sections
Almay Smart Shade Skintone Matching MakeupLight HUMAN OTC DRUG LABEL 2 0311-0784 LIQUID 4.80 mg TOPICAL OTC Monograph Drug 10 sections
BIOJUVE Microbiome-Safe Sheer Finish SPF 50 Sunscreen HUMAN OTC DRUG LABEL 2 0316-0300 LOTION 99.90 mg TOPICAL OTC Monograph Drug 10 sections
Blue Lizard Baby SPF 50 Sunscreen HUMAN OTC DRUG LABEL 2 0316-2036 LOTION 89.60 mg TOPICAL OTC Monograph Drug 11 sections
Blue Lizard Baby SPF 50 Sunscreen HUMAN OTC DRUG LABEL 2 0316-2036 LOTION 89.60 mg TOPICAL OTC Monograph Drug 11 sections
Blue Lizard Baby SPF 50 Sunscreen HUMAN OTC DRUG LABEL 2 0316-2036 LOTION 89.60 mg TOPICAL OTC Monograph Drug 11 sections
Blue Lizard Sensitive Sunscreen HUMAN OTC DRUG LABEL 2 0316-2045 LOTION 54 mg TOPICAL OTC Monograph Drug 11 sections
Blue Lizard Sensitive SPF 50 Sunscreen HUMAN OTC DRUG LABEL 2 0316-2046 LOTION 89.60 mg TOPICAL OTC Monograph Drug 14 sections